Table of Contents
A Praluent boost for Sanofi, and Regeneron
The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease. Praluent is an injectable prescription medicine co-developed by Sanofi and Regeneron Pharmaceuticals. It is a similar label extension as that of Amgen’s drug, Repatha, which was approved in December 2017.
EU grants Marketing Authorization to Zynquista
The European Commission has given an OK to Sanofi’s ‘Zynquista’ (sotagliflozin) for the treatment of adults suffering from type 1 diabetes. Developed jointly with a US firm Lexicon Pharmaceuticals, this is the first ever approved noninsulin therapy in the EU. Zynquista is once-daily doses of 200 mg and 400 mg, as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes (T1D) mellitus.
Novo Nordisk’s drug proves to be beneficial in cutting blood sugar
A major diabetes-drug of Novo Nordisk, Victoza, showed successful results in reducing blood sugar level in children with Type 2 diabetes. The clinical trials showed that Victoza injection is a safer, and efficient treatment option for pediatric patients.
Pfizer’s Talzenna steals the show
Pfizer’s PARP inhibitor, Talzenna (talazoparib) received positive feedback from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Talzenna is used for the treatment of adults with mutations in germline breast cancer susceptibility gene (gBRCA)1/2. Including Talzenna there are other thirteen drugs which got approval from the committee like Novo Nordisk’s Esperoct (turoctocog alfa pegol) and Alexion’s Ultomiris (ravulizumab).